医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Ganoderma Lucidum Spore Oil enhances the effect of cyclophosphamide via inhibiting programmed death-1 and prolongs the survival of H22 tumor-bearing mice

摘要OBJECTIVE:To investigate the effect of Ganoderma Lucidum Spore Oil(GLSO)on the tumor growth and survival of H22 tumor-bearing mice treated with cyclophosphamide(CTX),and explore the underlying mechanism.METHODS:Allograft H22 hepatocellular carcinoma mouse model was applied to investigate the effect of GLSO on the tumor growth and survival of animals,and Kaplan-Meier survival analysis was used to analyze the life span.Plasma biochemical examination was used to determine the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),urea(UREA)and creatinine(CRE).Western blot analysis was performed to detect Programmed Death-1(PD-1),Programmed Death Ligand 1(PD-L1),Janus Kinase 2(JAK2),phosphorylated Signal Transducer and Activator of Transcription 3(p-STAT3),and Signal Transducer and Activator of Transcription 3(STAT3)expression.RESULTS:GLSO increased the anti-tumor effect of CTX and prolonged the survival of H22 tumor-bearing mice treated with CTX.Meanwhile,GLSO increased the thymus index and showed no obvious toxicity to liver functions of animals.GLSO also decreased the level of UREA in H22 tumor-bearing mice treated with CTX.Furthermore,GLSO could inhibit the expression of PD-1 in spleen,which was independent of JAK2 expression and STAT3 phosphorylation.However,GLSO did not affect the expression of PD-L1,JAK2,and p-STAT3 in tumor tissue.CONCLUSION:GLSO could strengthen the anti-tumor effect of CTX and prolong the life span of H22 tumor-bearing mice,while the underlying mechanism might be relevant to the amelioration effect of thymus function and inhibition of PD-1 expression in spleen.Furthermore,these findings implied the promising role of GLSO in combination with CTX to extend the survival of patients in clinical chemotherapy of hepatocellular carcinoma.

更多
广告
作者 JIANG Zhaojian [1] CAI Hongfei [1] YUAN Cheng [1] CAO Lin [1] XU Wendong [1] HAN Yaming [1] ZHANG Qin [1] LI Jing [1] WANG Qin [2] LIU Juyan [3] 学术成果认领
作者单位 Guangzhou HanFang Pharmaceutical Company Limited,National Engineering Research Center of Pharmaceutical Processing Technology of Traditional Chinese Medicine and Drug Innovation,Guangdong Provincial Key Laboratory of Medicinal Lipids,Guangzhou 510240,China [1] Zhongshan Medical College,Sun Yat-sen University,Guangzhou 510080,China [2] Guangzhou Pharmaceutical Holdings Limited,Guangzhou 510130,China;National Engineering Research Center of Pharmaceutical Processing Technology of Traditional Chinese Medicine and Drug Innovation,Guangzhou 510240,China [3]
栏目名称
DOI 10.19852/j.cnki.jtcm.2024.04.003
发布时间 2024-11-11(万方平台首次上网日期,不代表论文的发表时间)
提交
  • 浏览1
  • 下载0
中医杂志(英文版)

中医杂志(英文版)

2024年44卷4期

652-659页

SCIMEDLINECSCDCA

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷